Company intelligence / Profile preview

AVEO Oncology

Boston, Massachusetts, United Statesaveooncology.com ↗

Ownership: Public · 051910.KS
Development stage: Commercial

Overview

AVEO's lead product FOTIVDA (tivozanib) received FDA approval on March 10, 2021 for the treatment of adult patients with relapsed or refractory renal cell carcinoma following two or more prior systemic therapies. The company has multiple clinical trials ongoing, including combination studies of tivozanib with immunotherapy agents.

Therapeutic areas: OncologyHematology
Modalities: Small moleculesMonoclonal antibodies (mAbs)IgG1 antibodies
Industry: Biotech

Drug pipeline

8 assets

tivozanib

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

LG ChemAstraZenecaMerck KGaACANbridge Life Sciences

Beyond the preview

Go deeper on AVEO Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVEO Oncology.

Explore the full profile